Riskpilot← Back to searchSign inGet full accessCambiotics ApS
APSActiveCVR 44572370Ole Maaløes Vej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20246 employees
Revenue 2025
DKK -3,3M
EBITDA margin
182.9%
Equity ratio
-103.0%
Financial strength
Net profit 2025
DKK -5,7M
6 employees
| Revenue | DKK -3,3M | — |
| EBITDA | DKK -6M | — |
| Net profit | DKK -5,7M | — |
| Total assets | DKK 5,5M | — |
| Equity | DKK -5,6M | — |
| Employees | 6 | — |
Legal name
Cambiotics ApS
CVR number
44572370
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
18. januar 2024
Share capital
DKK 63.029
Employees
6 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af en direktør i forening med et andet bestyrelsesmedlem.
Company purpose
Selskabets formål er forskning i, udvikling af, og kommercialisering af probiotiske og relaterede produkter for at forbedre sundhed.
Address
Ole Maaløes Vej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2025 |
|---|---|
| Revenue | -3.272 |
| Staff expenses | -2.713 |
| EBITDA | -5.986 |
| Depreciation & amort. | -0 |
| EBIT | -5.986 |
| Net financials | -371 |
| Profit before tax | -6.357 |
| Tax | -678 |
| Net profit | -5.679 |
| Item | 2025 |
|---|---|
| Total assets | 5.475 |
| Equity | -5.637 |
| Long-term debt | 10.400 |
| Short-term debt | 712 |
| Total debt | 11.112 |
EBITDA margin
-598558900.0%
This company
15.8%
Market median
-3788347568% vs market
20252025
Equity ratio
-103.0%
This company
38.2%
Market median
-370% vs market
20252025
Return on equity
-567895600.0%
This company
18.4%
Market median
-3086389230% vs market
20252025
Net profit margin
-567895600.0%
This company
8.1%
Market median
-7011056890% vs market
20252025
Asset turnover
-0.60×
This company
1.12×
Market median
-154% vs market
20252025
Debt / equity
1.97×
This company
0.62×
Market median
-218% vs market
20252025
- Annual report 2025Filed via CVR / Virk · Period 2024-01-18 – 2025-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JE | Founder | 2024 | — | — |
PH Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
TH Founder | Founder | 2024 | — | — |
AE Founder | Founder | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2025 | — | — | |
| Board of Directors | 2026 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ARTEFAKT HOLDING ApS | Company | 25.0% | 25.0% | 2026 |
| Individual | 10.0% | 10.0% | 2026 | |
BioInnovation Institute Fonden | Company | 10.0% | 10.0% | 2026 |
| Individual | 10.0% | 10.0% | 2026 | |
| Individual | 10.0% | 10.0% | 2026 | |
Danmarks Eksport- og Investeringsfond | Company | 5.0% | 5.0% | 2026 |
| Individual | 5.0% | 5.0% | 2026 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ARTEFAKT HOLDING ApS
Cambiotics ApS Board members of Cambiotics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| James Emanuel Dharendra Thaventhiran | Founder | 0 companies |
| Peter Holme Jensen | Chief Executive Officer | 0 companies |
| Torsten Høybye Bak Regueira | Founder | 0 companies |
| Anna Elisabeth Lindell | Founder | 0 companies |
| Steen Dannemann Andersen | Chairman | 0 companies |
| Matthew Gabriel Kaufman | Board of Directors | 0 companies |